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A possible role of aflatoxin B1 (AFB) in the etiology of human liver cancer has been suggested from
several epidemiological studies. This has been based upon the association between consumption of AFB-
contaminated food and the liver cancer incidence in different parts ofthe world. To further establish the
role ofAFB as a major factor, we initiated a pilot study in three different districts of Kenya to determine
the number of individuals exposed to significant amounts of AFB as measured by the urinary excretion
of 8,9-dihydro-8-(7-guanyl)-9-hydroxyaflatoxin B1 (AFB-Gua), an adduct formed between the ultimate
carcinogenic form ofAFB and nucleic acids. This product has previously been detected in urine from rats
treated with AFB. Urine collected at the outpatient clinics at the district hospitals were concentrated on
C18 Sep-Pak columns and analyzed by high-pressure liquid chromatography under two different chro-
matographic conditions. The chemical identity of the samples showing a positive response in both chro-
matographic systems was verified by synchronous scanning fluorescence spectrophotometry.
The highest number of individuals with detectable urinary AFB-Gua lived in either Murang'a district
or the neighboring Meru and Embu districts. In Murang'a district a rate of 12% was observed in the
January-March period, while only 1 of 32 patients (3%) had a detectable exposure in July-August. A
significant lower number of urine samples were positive for AFB-Gua in the other areas. However, the
collection of samples in these areas was during April-June, a period with lower AFB contamination of
the food. Ahighernumberofmen were positive forAFB-Gua inthe urinethan women. The results indicate
that a significant number of individuals in an area of high liver cancer risk has been exposed to AFB.
However, the present technology is not sensitive enough to detect lower level of AFB exposure, and the
method is too laborious to be used for a large epidemiological study.
Background
Aflatoxin B1, a mycotoxin produced by Aspergillus
flavus, is a potent liver carcinogen in rodents and non-
human primates (1,2). A number of epidemiological
studies have been conducted in Asia and Africa which
have shown a positive association between the dietary
intake of AFB and the incidence of liver cancer (3-5).
As the level of AFB was determined in either market
samples or in prepared food ready for consumption, it
has been difficult to calculate an exact individual ex-
posure level. An approach to determine the biological
dose of the carcinogen would be to measure AFB and/
or its metabolites in the body fluids, although it may
not represent the genotoxic dose ofAFB. Tsuboi et al.
(6) havereported the presence ofAFB in serum samples
of male Japanese subjects as determined by radioim-
munoassay and high-pressure liquid chromatography
(HPLC). Specific AFB metabolites or total AFB me-
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tabolites have been detected in human urine samples
by either chromatography or immunological methods
(7-9). Anaccuratemeasureforthegenotoxicdosewould
be to detect product(s) formed between the ultimate
form of the carcinogen and the genetic material. This
approach has successfully been demonstrated by de-
tectingcarcinogen-DNA adducts in the white blood cell
DNA isolated from individuals exposed to high level of
benzo(a)pyrene (10,11). In cells andtissuestreated with
carcinogens, the initial damage is quickly repaired by
enzymatic processes. The fate of these products is rel-
atively unexplored, but they may serve as good indi-
cators of carcinogen exposure. 7-Methylguanine (12) and
AFB-Gua (13) have been detected in rat urine after
treatment ofthe animals with dimethylnitrosamine and
AFB, respectively. These repair products are probably
formed by spontaneous depurination rather than by an
active DNA-repair process. The major AFB-DNA ad-
duct in vivo and in vitro is formed by the interaction of
AFB-8,9-oxide and the 7-position of guanine in DNA
(14). This adduct accounts for more than 80% of the
AFB-DNA adductsin rat liver2 hrafteradministration
of AFB (15). The same adduct was also detected in
cultured fetal liver explants after incubation with AFBAUTRUP ET AL.
(16). Formation of AFB-Gua in DNA induces a strong
positive charge in the imidazole ring, resulting in either
depurination ofAFB-Gua or an opening ofthe imidazole
ring to form two structurally related adducts, one of
which has been identified as 8,9-dihydro-9-(N5-formyl-
2',5' 66'-triamino-4'-oxo-N5-pyrimidyl)-9-hydroxy-AFB
(17,18). The latter adduct appears to be fairly stable in
the DNA, although an enzyme isolated from E. coli has
been shown to excise this product (19). The amount of
AFB-Gua in the urine after treating rats with AFB
corresponded to approximately 1% ofthe administered
dose (13,20), and a relationship between the dose of
AFB-Gua has also been detected for up to 72 hr in the
tissue culture media after treating a hepatocellular car-
cinoma cell line with AFB in the presence of liver mi-
crosomes. In a preliminary communication we have
reported the presence of a putative AFB-Gua product
in urine collected from individuals living in areas with
suspected exposure to AFB (21).
Procedure and Results
Urine samples (minimum 25 mL) were collected at
the outpatient clinic at Murang'a, Machakos, and Mak-
ueni District Hospitals and the Kenyatta National Hos-
pital, Nairobi using sterile, disposable containers. These
donors did not have a clinical history ofliver disorders,
but consulted the clinic for malaise. The age and sex
distribution ofthe donors is given in Table 1. The sam-
ples were immediately put on ice and transferred to the
laboratory for processing by a modification of the pro-
cedure by Bennett et al. (13). Samples were adjusted
to pH 5 and made 7% in methanol followed by centrif-
ugation at 4°C (1500 g for 10 min) to remove any par-
ticulates. The supernatant was submitted to initial clean-
up on aC18 Sep-Pakcartridge (WatersAssociates, Wal-
tham, MA., USA) using a Sep-Pak cartridge rack and
a maximum flow rate of 2mL/min. After washing with
5 mL 10% methanol and 5 mL 7% acetonitrile, the sam-
ples were shipped tothe USA. The cartridges were kept
at -70°C until analysis by high pressure chromatogra-
phy. The cartridges were eluted with 80% methanol (10
mL) and concentrated to 0.5 mL by using a Speedivac
evaporator and subjected to further clean-up by HPLC
with the use of a C18 Bondapak column and 18% ethanol-
10 mM ammonium formate (pH 5.1) as eluent with a
flow rate of 1 mL/min. Under these conditions, AFB-
Gua eluted at 21 min, and fractions from 20 to 23 min
were collected. Several urinary compounds absorbing
at 365 nm co-migrated with AFB-Gua on the C18 Bon-
dapak column, but this peak was resolved into several
components on an Ultrasil-Si (Altex) column using4.5%
acetonitrile (flow rate 1 mL/min). The eluent was mon-
itored at 365 nm (Waters model 44 spectrophotometer).
AFB-Gua eluted at 5.5 min on this column. The identity
of the putative AFB-Gua adduct was verified by coch-
romatography with minute amounts of synthetically
produced 3HAFB-Gua (22) once every day. The recov-
ery of AFB-Gua by this procedure was approximately
75%. The chemical identity ofthe positive samples was
verified by fluorescence spectrophotometry by use of
synchronous luminescence and photon counting (23). The
fluorescence was measured in a quartz cell (10 mm light
path), and both the excitation and emission monochro-
mators were set at 5 nm band width. The difference
was 34 nm, the emission being 34 nm higher than that
ofexcitation, and emission and excitation were scanned
simultaneously (synchronous scanning). Under these
conditions, both AFB-Gua isolated by HPLC from
chemicallymodified DNA andtheurinesamplespositive
in both HPLC systems gave a characteristic fluores-
cence with a peak emission of415 nm, when excited at
381 nm (21). When the samples were made alkaline no
bathochromic shift in the spectrum was observed. Pres-
ently, a total of 355 urine samples has been analyzed
for the presence ofAFB-Gua. A sample was considered
positive for AFB-Gua ifit gave a UV absorption at 365
nm in both HPLC systems and had the characteristic
synchronous fluorescent spectrum. The lower level of
detectability was 0.3 pmole AFB-Gua.
A total of 24 samples (6.7%) were positive for AFB-
Gua by these criteria (Table 2), with the highest fre-
quency in patients from Murang'a district. A relatively
high number of positive cases was also detected at the
outpatient clinic at Kenyatta National Hospital, Nai-
robi. However, when these cases were analyzed ac-
cording to the patients' home location (Table 3) only
patients living in Muranga, Kiambu, and Meru/Embu
districts were positive.
It is difficult to compare the rate ofAFB-Guapositive
samples in the different areas, as the collection took
Table 1. Age and sex distribution.
Male Female
% of cases % of cases
Number of positive for Number of positive for
Age group cases AFB-Gua cases AFB-Gua
11-20 38 7.9 37 10.8
21-30 36 8.3 73 6.8
31-40 24 12.5 36 8.3
41-50 12 0 25 0
51-60 17 11.8 19 0
>61 19 15.8 19 0
Total 146 9.0 209 5.5
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Table 2. Analysis of urine samples for AFB-GuaI.
No. of Cases
Collection site samples analyzed positivea
Kenyatta National
Hospital, Nairobi
January-March 128 11(8.6%)
Murang'a District Hospital
January-March 61 7(11.5%)
July-September 32 1(3.1%)
Machacos District Hospital
April-June 15 1(7%)
Makueni District Hospital
April-June 119 4(3%)
Total 355 24(6.7%)
aLimit of detectability was 0.3 pmole.
part in different seasons. It has previously been shown
that the consumption of AFB had a seasonal variation
(4). An interesting seasonal variation in the number of
positive cases was observed in Murang'a district: there
was a positive case rate of11.5% inJanuary-March but
only 3% in July-September. The sex and age distribu-
tion of the positive cases is shown in Table 1. A rela-
tively high number of positive cases was found among
older men, and the rate ofpositive cases was higher in
men than in women, although the difference was not
significant. Integration of the spectrum indicated that
the excreted amount of AFB-Gua was in the range of
0.3 to 3 pmoles/25mL of urine (21). If we assume that
humans excrete AFB-Gua at the same rate as rats, the
range of daily exposure in the patients with positive
reaction for AFB-Gua is 360 to 3600 ng/day. The lowest
amount detectedbyHPLC and synchronousfluoroscopy
corresponds to the estimated exposure levels at the lower
altitude (high exposure) in Muranga district as deter-
minedby analysis oftheprepared food samples for AFB
(24). Urine samples collected from residents in the Nai-
robi area served as the controls, because it is assumed
that the diet here is less likely to be contaminated with
AFB because ofthe better storage facilities forfood and
ahigher socioeconomic level. All the positive cases from
Kenyatta National Hospital lived in the rural area around
Nairobi City, where it may be assumed that the food
was eitherbought at the local open market or cultivated
and stored by the patients themselves. A few of the
samples showed two peaks in the synchronous fluores-
Table 3. Analysis of AFB-GuaI in urine from patients collected
at Kenyatta National Hospital.
No. of AFB-Gual
samples positive
District analyzed casesa
Kiambu 39 3(7.7)
Machakos 11 0
Meru/Embu 9 3(33.3)
Murang'a 25 5(20.0)
Others, including Nairobi 44 0
Total 128 11(8.6)
aLimit of detectability was 0.3 pmole.
cent spectrum with peak emission at 415 nm and 435
nm. The chemical identity ofthe second product is pres-
ently unknown, but it does not represent the ring-opened
form of AFB-Gua.
Perspective
Detection ofcarcinogen-DNA adducts in urine or blood
samples is indirect prooffor in vivo activation ofchem-
ical carcinogens by humans and constitutes a very spe-
cific method for monitoring exposure to carinogenic
compounds. The presence ofAFB-Guaintheurine sam-
ples collected in various districts of Kenya is an indi-
cation that biological activation of the carcinogen has
taken place, and that the ultimate carcinogenic form of
AFB has reacted with cellular nucleic acids ortheirpre-
cursors. We cannot rule out the possibility that AFB-
Gua is from cellular RNA rather than DNA, as the
adducts are identical in both nucleic acids (24). Fur-
thermore, the AFB-Gua could also originate in an organ
other than the liver, although this organ is considered
the major site of activation of AFB in experimental
animals. The presence of AFB-Gua in urine may be an
indication of the presence of other potential mutagenic
lesion in the liver such as the ring-opened form ofAFB-
Gua and apurinic sites. both lesions have been consid-
ered to be responsible for the mutagenic effect ofAFB
(25,26). However, further studies are required to es-
tablish an association between dietary intake of AFB,
excretion of AFB-Gua in the urine, and the incidence
of liver cancer. Before a larger epidemiological study
should be initiated new analytical procedures should be
developed. Application ofantibodies against total AFB
metabolites (7,8) and AFB-DNA (27) in immunological
methods could be ofgreat interest both forisolation and
quantitation ofAFB-Gua in human urine samples. Chu
et al. (28) has produced an antiserum against aflatoxin
B2a that recognizes AFB-Gua and other AFB metabo-
lites. The lattercompounds willinterfere with detection
ofAFB-Guaintheurine and aninitialcleanupbyHPLC
will be required. The sensitivity is less (50% inhibition)
than in the reported method. Monoclonal antibodies
against AFB-DNA have not shown any cross-reactivity
with AFB-Gua using the competitive Useria assay.
Donahue et al. (8) has taken a different approach by
alkylation of the AFB-Gua isolated by HPLC with 3H-
dimethyl sulfate of high specific activity followed by
HPLC analysis of the hydrolyzed product, 9-methyl-
guanine. The sensitivity of this method is higher but
the results are difficult to reproduce due to the many
steps involved, and the method is too laborious forlarge
epidemiological surveys. The approach taken by Sun
and coworkers for identification and quantification of
AFB metabolites is presently the most promising. Ur-
ine samples were concentrated by affinity chromatog-
raphy using antibodies against AFB metabolites followed
by HPLC analysis ofthe ethanol eluate (7). Even with
improved sensitivity, the detection ofAFB-Guainurine
may be an underestimation of AFB exposed individual
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as AFB-Gua will only represent exposure within the
last24to48hr. However, the rate ofAFB-Gua-positive
cases in the reported study corresponds to the number
of patients with positive serology for active hepatitis
infection, anothermajoretiological agentinhumanliver
cancer.
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